3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
20
Other hematologic neoplasm
6
Plasma cell
3
Myeloid
2
Sarcoma
1
Genitourinary
1
Dermatologic
1
Conditions
Sarcoma
286
Gliosarcoma
149
Glioblastoma
149
Brain Neoplasms
90
Osteosarcoma
84
Glioma
68
Gastrointestinal Stromal Tumors
68
Rhabdomyosarcoma
65
Lymphoma, Non-Hodgkin
59
Astrocytoma
59
Recurrence
57
Dendritic Cell Sarcoma, Interdigitating
57
Sarcoma, Ewing
55
Neoplasms
54
Precursor Cell Lymphoblastic Leukemia-Lymphoma
50
Lymphoma
50
Burkitt Lymphoma
49
Central Nervous System Neoplasms
48
Neuroblastoma
47
Lymphoma, Large B-Cell, Diffuse
47
Lymphoma, Follicular
46
Neoplasm Metastasis
45
Lymphoma, Mantle-Cell
45
Leiomyosarcoma
44
Oligodendroglioma
43
Leukemia, Myeloid, Acute
43
Liposarcoma
42
Lymphoma, B-Cell, Marginal Zone
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Hodgkin Disease
41
Interventions
pembrolizumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Immune System Diseases
×
Sarcoma
×
Clear all
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts